The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1246
October 23, 2006
View Complete Issue         Table of Contents 2019 
Ranibizumab (Lucentis) for Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ranibizumab (Lucentis) for Macular Degeneration
October 23, 2006 (Issue: 1246)
The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab (Avastin), which is FDA-approved for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ranibizumab (Lucentis) for Macular Degeneration
Article code: 1246a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.